TWST Logo

Twist Bioscience Corporation (TWST) 

NASDAQ
Market Cap
$2.85B
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
927 of 960
Rank in Industry
52 of 52

Largest Insider Buys in Sector

TWST Stock Price History Chart

TWST Stock Performance

About Twist Bioscience Corporation

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical …

Insider Activity of Twist Bioscience Corporation

Over the last 12 months, insiders at Twist Bioscience Corporation have bought $0 and sold $6.83M worth of Twist Bioscience Corporation stock.

On average, over the past 5 years, insiders at Twist Bioscience Corporation have bought $191,048 and sold $61.52M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 10,000 shares for transaction amount of $132,000 was made by Cho Dennis (See Remarks) on 2023‑05‑10.

List of Insider Buy and Sell Transactions, Twist Bioscience Corporation

2024-12-16SaleSee Remarks
133
0.0002%
$46.81$6,225-0.54%
2024-12-06SaleChief Executive Officer
2,216
0.0037%
$52.70$116,792-8.13%
2024-12-06SaleSVP of Human Resources
860
0.0014%
$52.70$45,325-8.13%
2024-12-06SaleSee Remarks
367
0.0006%
$52.70$19,342-8.13%
2024-12-06SaleChief Accounting Officer
226
0.0004%
$52.70$11,911-8.13%
2024-11-25SaleChief Accounting Officer
789
0.0012%
$44.20$34,871+5.65%
2024-11-11SaleChief Executive Officer
7,968
0.0138%
$48.00$382,448+2.20%
2024-11-11SalePresident and COO
10,340
0.0179%
$48.00$496,299+2.20%
2024-11-11SaleSVP of Human Resources
1,347
0.0023%
$48.00$64,653+2.20%
2024-11-11SaleSee Remarks
1,507
0.0026%
$48.00$72,333+2.20%
2024-11-11Saledirector
3,600
0.0062%
$47.26$170,139+2.20%
2024-11-06SaleChief Executive Officer
14,334
0.0243%
$44.60$639,368+5.06%
2024-11-06SalePresident and COO
6,239
0.0106%
$44.60$278,291+5.06%
2024-11-06SaleSVP of Human Resources
5,519
0.0093%
$44.60$246,175+5.06%
2024-11-06SaleSee Remarks
1,811
0.0031%
$44.60$80,780+5.06%
2024-11-06SaleChief Financial Officer
4,160
0.007%
$44.60$185,557+5.06%
2024-11-06SaleChief Accounting Officer
1,448
0.0025%
$44.60$64,588+5.06%
2024-11-04SaleChief Executive Officer
4,841
0.008%
$41.56$201,211+12.96%
2024-11-04SalePresident and COO
2,681
0.0044%
$41.56$111,433+12.96%
2024-11-04SaleSVP of Human Resources
1,057
0.0017%
$41.56$43,933+12.96%

Insider Historical Profitability

61.97%
Cho DennisSee Remarks
113487
0.1912%
$47.94119+82.06%
ARCH Venture Partners VIII, LLC10 percent owner
2407422
4.0559%
$47.9410+78.29%
BARTHELEMY NICOLAS
13939
0.0235%
$47.9411+9.24%
CRANDELL KEITHdirector
486
0.0008%
$47.9412+78.29%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
ARK Investment Management LLC$238.25M11.936.94M-3.73%-$9.24M0.82
BlackRock$198.14M9.925.77M-2.9%-$5.92M<0.01
The Vanguard Group$187.41M9.385.46M-0.24%-$449,117.90<0.01
Artisan Partners$159.25M7.974.64M+24.66%+$31.51M0.24
JPMorgan Chase$123.99M6.213.61M-21.71%-$34.38M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.